drugset / Trial / NCT00964249

Phase I Study of GW642444M in Healthy Japanese Male Subjects

NCT00964249

Phase 1 Completed 32 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, double blind, placebo controlled, parallel-group, 7 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose of GW642444M from a novel dry powder device in healthy Japanese male subjects.

Timeline

Start
2008-09-20
Primary completion
2008-12-01
Completion
2008-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilanterol Other / unclassified 12.5 ug Inhaled
Subject Vilanterol Other / unclassified 25 ug Inhaled